Integrin Beta1 Polypeptides Neutralize Amyloid Beta Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective targets and compounds to mitigate the toxic effects of beta-amyloid peptide (Aβ) deposition, which is associated with various neurodegenerative diseases, including Alzheimer's, as the mechanisms of Aβ-induced cell death and toxicity are not fully understood.
Innovation Solution
Polypeptides containing the amino acid sequence 1-20 of integrin β1 are shown to specifically bind to Aβ 1-42, preventing its toxic action on astrocytes by reducing Rac1 activation, reactive oxygen species formation, astrogliosis, and GRP78 expression, thereby offering a potential therapeutic approach for diseases characterized by amyloid deposits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If Aβ peptide is produced through amyloidogenic pathway, then neurotoxic effects are generated, but therapeutic targets and effective treatments are lacking
Solution Approach 1:
The patent introduces an engineered antibody as an intermediary molecule that specifically binds to Aβ peptide, preventing it from interacting with cellular receptors and exerting toxic effects. This antibody mediator bridges the gap between the harmful Aβ peptide and the desired therapeutic outcome by neutralizing its toxicity without requiring complete elimination of the peptide
Solution Approach 2:
The invention converts the harmful Aβ peptide into a beneficial target for therapy. By designing an antibody that specifically recognizes and binds to Aβ, the previously harmful substance becomes the focal point of a therapeutic strategy. The antibody-Aβ complex can be cleared or neutralized, transforming the toxic peptide into a target that enables protective immune responses or controlled removal
2Difficulty of detecting and measuring
If Aβ peptide binds to membrane receptors, then rapid cell death is induced, but mechanisms of toxicity are not fully understood
Solution Approach 1:
The engineered antibody is designed to bind to Aβ peptide in advance, preventing it from subsequently binding to membrane receptors and inducing cell death. This preliminary blocking action occurs before the toxic pathway is activated, effectively intercepting the Aβ peptide and preventing the cascade of events that lead to neuronal death
Solution Approach 2:
The antibody serves as an intermediary that replaces the natural interaction between Aβ peptide and membrane receptors. Instead of Aβ directly binding to receptors and triggering cell death, the antibody intervenes by binding to Aβ first, thereby preventing the harmful receptor interaction while providing a controlled, therapeutically beneficial binding event
3Object-affected harmful factors
If polypeptides containing integrin β1 amino acids 1-20 are used, then Aβ binding is prevented, but therapeutic compound availability is limited
Solution Approach 1:
The patent creates a universal therapeutic platform by engineering an antibody with multiple functional capabilities. The antibody can bind to Aβ peptide, prevent its toxic interactions, and potentially facilitate clearance. This single molecular entity performs multiple protective functions, replacing the need for multiple different therapeutic compounds targeting various aspects of Aβ pathology
Solution Approach 2:
The invention modifies the molecular parameters of the therapeutic agent by using protein engineering to create an antibody with optimized binding characteristics. By changing the structural and functional parameters of the antibody (such as affinity, specificity, and stability), the therapy can effectively neutralize Aβ while overcoming limitations of previous approaches that used simpler polypeptides
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptides effectively inhibit Aβ 1-42-induced toxicity in astrocytes, suggesting their utility in treating diseases like Alzheimer's by reducing cellular damage and amyloid-related pathology.
Implementation Method 1
polypeptides containing a region formed by amino acids 1-20 of integrin β1 are capable of binding specifically to amyloid β-protein 1-42
Data Source
AI summary
The present invention relates to the development of polypeptides useful for the treatment of diseases associated with amyloid deposits, and more specifically for the treatment of Alzheimer's disease. The invention also relates to compositions comprising the developed polypeptides and to a method for the identification of compounds useful for the treatment of diseases associated with the formation of amyloid deposits.